|
1. Definition, classification, removal, and retrieval of polyps
|
3
|
ESGE recommends that all polyps be resected except for diminutive (≤ 5 mm) rectal and rectosigmoid polyps that are predicted with high confidence to be hyperplastic. (High-quality evidence; strong recommendation.)
|
Level I/II/III: No adjustment.
|
4
|
ESGE recommends retrieval of all resected polyps for histopathological examination. In expert centers, where optical diagnosis may be made with a high degree of confidence, a “resect and discard” strategy may be considered for diminutive polyps. (Moderate-quality evidence; strong recommendation.)
|
Level I: Resect and discard if histopathology is unavailable.
Level II: No adjustment.
Level III: No adjustment.
|
|
2. Resection of polyps < 20 mm in size
|
|
2.1 Resection of diminutive polyps (≤ 5 mm)
|
5
|
ESGE recommends cold snare polypectomy (CSP) as the preferred technique for removal of diminutive polyps (size ≤ 5 mm). This technique has high rates of complete resection, adequate tissue sampling for histology, and low complication rates. (High-quality evidence; strong recommendation.)
|
Level I: Omit resection or resect and discard.
Level II: No adjustment.
Level III: No adjustment.
|
|
2.2 Resection of small polyps (6–9 mm)
|
8
|
ESGE recommends snare polypectomy for sessile polyps 6–9 mm in size. ESGE recommends against the use of biopsy forceps for resection of such polyps because of high rates of incomplete resection. (High-quality evidence; strong recommendation.)
|
Level I: Referral to a less resource-limited center.
Level II: No adjustment.
Level III: No adjustment.
|
9
|
ESGE suggests CSP for sessile polyps 6–9 mm in size because of its superior safety profile, although evidence comparing efficacy with HSP is lacking. (Moderate-quality evidence; weak recommendation.)
|
Level I: Referral to a less resource-limited center.
Level II: No adjustment.
Level III: No adjustment.
|
|
2.3 Polypectomy of sessile polyps (10–19 mm)
|
10
|
ESGE suggests hot snare polypectomy (HSP) (with or without submucosal injection) for removal of sessile polyps 10–19 mm in size. In most cases deep thermal injury is a potential risk and thus submucosal injection prior to HSP should be considered. (Low-quality evidence; strong recommendation.)
|
Level I: Referral to a less resource-limited center, or if that is impossible, surgical resection.
Level II: Submucosal injection of normal saline prior to polypectomy.
Level III: No adjustment.
|
|
2.4 Polypectomy of pedunculated lesions
|
12
|
ESGE recommends HSP for pedunculated polyps. To prevent bleeding, in pedunculated colorectal polyps with head ≥ 20 mm or a stalk ≥ 10 mm in diameter, ESGE recommends pretreatment of the stalk with injection of dilute adrenaline and/or mechanical hemostasis. (Moderate-quality evidence; strong recommendation.)
|
Level I/II: Referral to a less resource-limited center, or if that is impossible, surgical resection. Endoscopic treatment without access to injection therapy or mechanical hemostasis is only recommend in emergency cases (bleeding).
Level III: No adjustment.
|
|
2.5 Which polyps should be removed by an expert endoscopist in a referral or tertiary center?
|
13
|
Large (≥ 20 mm) sessile and laterally spreading or complex polyps, should be removed by an appropriately trained and experienced endoscopist, in an appropriately resourced endoscopy center. (Moderate-quality evidence; strong recommendation)
|
Level I: Referral to a less resource -limited center, or if that is impossible, surgical resection. Endoscopic treatment without access to injection therapy or mechanical hemostasis is only recommend in emergency cases (bleeding). Level II: Endoscopic treatment without access to injection therapy or mechanical hemostasis is only recommend in emergency cases (bleeding). Level III: No adjustment.
|
|
2.6 Polyps requiring other (non-snare) techniques, e. g. endoscopic submucosal dissection (ESD) or surgery
|
14
|
The majority of colonic and rectal lesions can be effectively removed in a curative way by standard polypectomy and/or by EMR. (Moderate-quality evidence; strong recommendation.)
|
Level I/II/III: No adjustment.
|
15
|
En bloc resection techniques such as en bloc EMR, ESD, or surgery should be the techniques of choice in cases of suspected superficial invasive carcinoma. (Moderate-quality evidence; strong recommendation.)
|
Level I: Referral to a less resource-limited center, or if that is impossible, surgical resection. Endoscopic treatment without access to injection therapy or mechanical hemostasis is only recommend in emergency cases (bleeding.)
Level II: Referral to a less resource-limited center, or if that is impossible, surgical resection. Endoscopic treatment without access to injection therapy or mechanical hemostasis is only recommend in emergency cases (bleeding).
Level III: En bloc EMR or surgery.
|
16
|
ESD can be considered for removal of colonic and rectal lesions with high suspicion of superficial submucosal invasion and which otherwise cannot be removed en bloc by standard polypectomy or EMR. (Moderate-quality evidence; strong recommendation).
|
Level I: Surgical resection.
Level II: Surgical resection.
Level III: Surgical resection.
|
18
|
ESGE recommends that endoscopic cure for lesions resected by EMR should be confirmed at surveillance colonoscopy by advanced endoscopic imaging and systematic biopsy. (Low-quality evidence; strong recommendation.)
|
Level I: Biopsy.
Level II: Biopsy.
Level III: No adjustment.
|
19
|
ESGE recommends that suspected residual or recurrent adenoma identified at surveillance colonoscopy is snare-resected within the same procedure. Where snare resection is not possible, ablation should be performed. (Moderate-quality evidence; strong recommendation.)
|
Level I: Referral to a less ressource dependent center, or if that is impossible, consider surgical resection.
Level II: Snare resection or referral to a less resource-limited center, or if that is impossible, consider surgical resection.
Level III: No adjustment.
|
20
|
ESGE recommends the use of advanced endoscopic imaging to identify the potential presence of superficial submucosal invasion. (Moderate-quality evidence; strong recommendation.)
|
Level I: White light imaging.
Level II: Standard chromoendoscopy.
Level III: No adjustment.
|
21
|
ESGE suggests that when advanced imaging is not available, standard chromoendoscopy may be beneficial. (Moderate-quality evidence; strong recommendation.)
|
Level I: White light imaging.
Level II: No adjustment.
Level III: No adjustment.
|
22
|
ESGE recommends that polyps with advanced endoscopic imaging characteristics of deep submucosal invasion should not be considered for endoscopic treatment and should be referred for surgery. (Moderate-quality evidence; strong recommendation.)
|
Level I/II/III: No adjustment.
|
23
|
ESGE recommends that polyps without characteristics of deep submucosal invasion should not be referred for surgery without consultation with an expert endoscopy center for evaluation for polypectomy/EMR. (Low-quality evidence, strong recommendation.)
|
Level I: Referral to a less resource limited center, or if that is impossible, surgical resection.
Level II: Referral to a less resource -limited center, or if that is impossible, surgical resection.
Level III: No adjustment.
|
|
2.7 Colonic tattooing: which lesions should be tattooed, and what is the best technique and location for tattoo placement?
|
24
|
ESGE recommends that lesions that may need to be located at future endoscopic or surgical procedures should be tattooed during colonoscopy. (Low-quality evidence, strong recommendation.)
|
Level I: Use India ink and careful description of the location of the lesion.
Level II: Use India ink and careful description of the location of the lesion
Level III: No adjustment.
|
25
|
ESGE recommends sterile carbon particle suspension as the preferred tattoo agent. (Low-quality evidence, strong recommendation.)
|
Level I: and careful description of the location of the lesion
Level II: No adjustment.
Level III: No adjustment.
|
|
3. Endoscopic mucosal resection (EMR) for sessile laterally spreading lesions ≥ 20 mm in size
|
30
|
ESGE suggests the use of submucosal injectates for EMR that are more viscous than normal saline and whose safety has been proven, including succinylated gelatin, hydroxyethyl starch, or glycerol, since their use is associated with superior technical outcomes and reduced procedural time. (High-quality evidence; weak recommendation.)
|
Level I: Referral to a less resource- limited center, or if that is impossible, surgical resection.
Level II: Use normal saline.
Level III: No adjustment.
|
31
|
ESGE recommends that a biologically inert blue dye such as indigo carmine should be incorporated into the submucosal injection solution to facilitate identification of fluid cushion extent, lesion margins, and deep mural injury. (Moderate-quality evidence; strong recommendation.)
|
Level I/II/III: No adjustment.
|
35
|
ESGE suggests that where complete snare excision EMR has been achieved, the role of adjuvant thermal ablation of the EMR resection margins to prevent recurrence requires further study. (Low-quality evidence; weak recommendation.)
|
Level I/II/III: No adjustment.
|
36
|
ESGE recommends that when a lesion appears suitable for EMR, but does not lift with submucosal injection, referral should be made to an expert endoscopist in a tertiary center. (Moderate-quality evidence, strong recommendation.)
|
Level I/II/III: No adjustment
|
37
|
ESGE recommends that all EMR specimens be retrieved for histological evaluation. (Moderate-quality evidence; strong recommendation.)
|
Level I/II: no adjustment, where histological evaluation is available and affordable for patients;
Level III: no adjustment
|
|
4. Equipment considerations for polypectomy and EMR
|
|
4.1 Type of current
|
38
|
ESGE suggests the use of a microprocessor-controlled electrocautery generator for polypectomy. (Low-quality evidence; weak recommendation.)
|
Level I/II/III: No adjustment
|
41
|
ESGE suggests the use of carbon dioxide (CO2) insufflation during colonoscopy and polypectomy. (Low-quality evidence, strong recommendation.)
|
Level I/II: Use air for insufflation if CO2 is not available;
Level III: no adjustment
|
|
4.2 Carbon dioxide (CO2) insufflation
|
|
42
|
ESGE recommends the use of CO2 insufflation for EMR. (Moderate-quality evidence; strong recommendation.)
|
Level I/II/III: Use air for insufflation if CO2 is not available.
|
|
4.4 Fluid pump
|
43
|
ESGE suggests the use of a fluid jet pump to enable efficient irrigation of the colonic mucosa and polypectomy sites and management of bleeding. (Low-quality evidence; weak recommendation.)
|
Level I: Manual water irrigation;
Level II/III: No adjustment.
|
|
5. Polypectomy-associated adverse events: definitions and management
|
|
5.1 Bleeding
|
44
|
For intraprocedural bleeding, ESGE recommends endoscopic coagulation (snare-tip soft coagulation or coagulating forceps) or mechanical therapy, with or without the combined use of dilute adrenaline injection. (Low-quality evidence; strong recommendation.)
|
Level I: Adrenalin injection.
Level II/III: No adjustment.
|
46
|
ESGE suggests that there may be a role for mechanical prophylaxis (e. g. clip closure of the mucosal defect) in certain high-risk cases after polypectomy or EMR. This decision must be individualized based on the patient’s risk factors. (Low-quality evidence; weak recommendation.)
|
Level I: Referral to level II/III centers or to surgery.
Level II: Attempt high-risk EMR only when all accessories and expertise are available. Otherwise refer to a less resource-limited centre or for surgery.
Level III: No adjustment.
|
47
|
Patients admitted to hospital with delayed bleeding who are hemodynamically stable, without ongoing bleeding, may be initially managed conservatively. If intervention is required, ESGE recommends colonoscopy as the first-line investigation. (Moderate-quality evidence, strong recommendation.)
|
Level I/II/III: No adjustment
|
48
|
When the polypectomy site is identified during colonoscopy for post-polypectomy bleeding, and active bleeding or other high-risk stigmata are identified, ESGE recommends forceps coagulation or mechanical therapy, with or without the combined use of dilute adrenaline injection. (Moderate-quality evidence; strong recommendation.)
|
Level I: Adrenalin injection.
Level II/III: No adjustment.
|
|
5.2 Prevention of perforation
|
49
|
ESGE recommends careful inspection of the post-resection mucosal defect to identify features of or risk factors for impending perforation. Where these risk factors are identified, clip closure should be performed. (Moderate-quality evidence; strong recommendation.)
|
Level I: Clip closure if available.
Level II/III: No adjustment.
|
|
5.3 Audit of adverse events
|
50
|
ESGE recommends audit of adverse events. (Moderate-quality evidence; strong recommendation.)
|
Level I/II/III: No adjustment.
|
|
6. How is the histology specimen best managed and reported upon? Processing, analysis, and reporting (minimum reporting standards)
|
51
|
ESGE recommends that polypectomy specimens be placed in separate containers, one for each lesion. Local factors may play a role in whether this is feasible. Fixation should be by buffered 10 % formalin. The pathologist should measure the size of each specimen in millimeters. (Moderate-quality evidence; strong recommendation.)
|
Level I/II/III: No adjustment.
|
|
7. Diagnosis of lesions in the adenoma-carcinoma sequence
|
|
7.2 Histological findings that require further action
|
57
|
The opinion of a second histopathologist may be warranted when reviewing high-risk features. (Low-quality evidence; weak recommendation.)
|
Level I/II/III: No adjustment.
|